trastuzumab deruxtecan + pembrolizumab

**Trastuzumab deruxtecan + pembrolizumab** is an investigational combination therapy comprising trastuzumab deruxtecan, an antibody-drug conjugate that targets HER2 (human epidermal growth factor receptor 2), and pembrolizumab, a monoclonal antibody that inhibits PD-1 (programmed death receptor-1). Trastuzumab deruxtecan delivers a cytotoxic topoisomerase I inhibitor to HER2-expressing cancer cells, leading to cell death, while pembrolizumab potentiates antitumor immunity by preventing PD-1/PD-L1-mediated immune evasion. The combination is primarily under investigation for HER2-positive and HER2-low metastatic breast cancer, endometrial cancer, and advanced gastric/esophageal/gastroesophageal junction adenocarcinoma, aiming to produce additive or synergistic antitumor effects by combining targeted cytotoxic and immune checkpoint blockade mechanisms[1][2][4][7][10].

Brand names

Keytruda (for pembrolizumab)Enhertu (for trastuzumab deruxtecan)

Other names

trastuzumab deruxtecanpembrolizumabDS-8201aDS8201aDS 8201aT-DXd